Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s axing a hemophilia candidate inherited in its 2019 buyout of Spark ...
It's summertime in the NBA, so the ample free time is a perfect opportunity to reflect and learn about the league's history. While the Oklahoma City Thunder are a relatively fresh franchise, they ...
ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche plans to complete its $4.3 billion (3.35 billion pounds) takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British ...
Late-to-the-game Roche has finally made a move in gene therapy, one of the biopharma industry’s most sought-after and expensive classes of medications. And it's a move that will vault the Swiss ...
Noninferiority clinical trials have become a major tool for the evaluation of drugs, devices, biologics, and other medical treatments. Treatment with placebo or with a no-treatment control in a study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback